Confronting chemobrain: an in-depth look at survivors' reports of impact on work, social networks, and health care response

Nelli Boykoff, Mona Moieni, Saskia Karen Subramanian, Nelli Boykoff, Mona Moieni, Saskia Karen Subramanian

Abstract

Introduction: Mild cognitive impairment following chemotherapy is one of the most commonly reported post treatment symptoms by breast cancer survivors. This deterioration in cognitive function, commonly referred to as "chemobrain" or "chemofog," was largely unacknowledged by the medical community until recent years. Although chemobrain has now become the subject of more vigorous exploration, little is known about this specific phenomenon's psychosocial impact on breast cancer survivors. This research documents in-depth the effects that cognitive impairment has on women's personal and professional lives, and our data suggest that greater attention needs to be focused on this arena of survivorship.

Methods: The results are based on an in-depth qualitative study of 74 white and African American breast cancer survivors in California who experience post-treatment side effects. The data reported herein were obtained through the use of focus groups and in-depth interviews.

Results: Our data indicate that cognitive impairment can be problematic for survivors, with many asserting that it is their most troublesome post treatment symptom. Survivors report diminished quality of life and daily functioning as a result of chemobrain. Respondents detail a range of coping strategies that they are forced to employ in order to manage their social and professional lives.

Discussions/conclusions: Chemobrain significantly impairs a proportion of cancer survivors, at great cost to them economically, emotionally, and interpersonally. This suggests that more research needs to be conducted on the psychosocial ramifications of post treatment symptoms in order to inform the efforts of the medical and mental health communities as well as the support networks of survivors.

Implications for cancer survivors: A better and broader understanding of the effects of cognitive impairment both in the medical community and among lay people could pave the way for improved social and psychological services for this population.

References

    1. National Cancer Institute. Estimated US cancer prevalence. Updated May 13, 2009. Available from: .
    1. American Cancer Society. What are the key statistics for breast cancer? Detailed Guide, Breast Cancer 2009; Available from: .
    1. Grober SE. Resources for treatment of chemotherapy-related cognitive difficulty. Cancer Pract. 2002;19:216–8. doi: 10.1046/j.1523-5394.2002.104005.x.
    1. Wienke MH, Dienst E. Neuropsychological assessment of cognitive functioning following chemotherapy for breast cancer. Psychooncology. 1995;4:61–6. doi: 10.1002/pon.2960040108.
    1. Schagen SB, Van Dam FS, Muller MJ, Boogerd W, Lindeboom J, Bruning PF. Cognitive deficits after postoperative adjuvant chemotherapy for breast carcinoma. Cancer. 1999;85:640–50. doi: 10.1002/(SICI)1097-0142(19990201)85:3<640::AID-CNCR14>;2-G.
    1. Van Dam FS, Schagen SB, Mueller MJ, Boogerd W, van der Wall E, Droogleever Fortuyen ME, et al. Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: high-dose vs. standard-dose chemotherapy. J Natl Cancer Inst. 1998;90:182–3. doi: 10.1093/jnci/90.3.182.
    1. Brezden CB, Phillips KA, Abdolell M, Bunston T, Tannock IF. Cognitive function in breast cancer patients receiving adjuvant chemotherapy. J Clin Oncol. 2000;18:2695–701.
    1. Ahles TA, Saykin AJ, Furstenberg CT, Cole B, Mott LA, Skalla K, et al. Neuropsychologic impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma. J Clin Oncol. 2002;20:485–93. doi: 10.1200/JCO.20.2.485.
    1. Castellon SA, Ganz PA, Bower JE, Petersen L, Abraham L, Greendale GA. Neurocognitive performance in breast cancer survivors exposed to adjuvant chemotherapy and tamoxifen. J Clin Exp Neuropsychol. 2004;26:955–69. doi: 10.1080/13803390490510905.
    1. Shilling V, Jenkins V, Morris R, Deutsch G, Bloomfield D. The effects of adjuvant chemotherapy on cognition in women with breast cancer—preliminary results of an observational longitudinal study. Breast. 2005;14:142–50. doi: 10.1016/j.breast.2004.10.004.
    1. Bender CM, Sereika SM, Berga SL, Vogel VG, Brufsky AM, Paraska KK, et al. Cognitive impairment associated with adjuvant therapy in breast cancer. Psycho-Oncology. 2006;15:422–30. doi: 10.1002/pon.964.
    1. Hurria A, Rosen C, Hudis C, Zuckerman E, Panageas KS, Lachs MS, et al. Cognitive function of older patients receiving adjuvant chemotherapy for breast cancer: a pilot prospective longitudinal study. J Am Geriatr Soc. 2006;54:925–31. doi: 10.1111/j.1532-5415.2006.00732.x.
    1. Raffa RB, Duong PV, Finney J, Garber DA, Lam LM, Matthew SS. Is chemo-fog/chemo-brain caused by cancer chemotherapy? J Clin Pharm Ther. 2006;31:129–38. doi: 10.1111/j.1365-2710.2006.00726.x.
    1. Silverman DH, Dy CJ, Castellon SA, Lai J, Pio BS, Abraham L, et al. Altered frontocortical, cerebellar, and basal ganglia activity in adjuvant-treated breast cancer survivors 5–10 years after chemotherapy. Breast Cancer Res Treat. 2007;103:303–11. doi: 10.1007/s10549-006-9380-z.
    1. Nelson CJ, Nandy N, Roth AJ. Chemotherapy and cognitive deficits: mechanisms, findings, and potential interventions. Palliat Support Care. 2007;5:273–80.
    1. Kannarkat G, Lasher EE, Schiff D. Neurologic complications of chemotherapy agents. Curr Opin Neurol. 2007;20:719–25.
    1. Tangpong J, Cole MP, Rukhsana S, Estus S, Vore M, St. Clair W, et al. Adriamycin-mediated nitration of manganese superoxide dismutase in the central nervous system: insight into the mechanism of chemobrain. J Neurochem. 2007;100:191–201. doi: 10.1111/j.1471-4159.2006.04179.x.
    1. Jackson GE. Chemo brain—a psychotropic drug phenomenon? Med Hypotheses. 2008;70:572–7. doi: 10.1016/j.mehy.2007.06.019.
    1. Wefel J, Lenzi R, Theriault R, Buzdar A, Cruickshank MC. ‘Chemobrain’ in breast carcinoma? A prologue. Cancer. 2004;101:466–75. doi: 10.1002/cncr.20393.
    1. Donovan K, Small B, Andrykowski M, Schmitt F, Munster P, Jacobsen P. Cognitive functioning after adjuvant chemotherapy and /or radiotherapy for early-stage breast carcinoma. Cancer. 2005;104:2499–507. doi: 10.1002/cncr.21482.
    1. Jenkins V, Shilling V, Deutsch G, Bloomfield D, Morris R, et al. A 3-year prospective study of the effects of adjuvant treatments on cognition in women with early stage breast cancer. Br J Cancer. 2006;94:828–34. doi: 10.1038/sj.bjc.6603029.
    1. Shilling V, Jenkins V. Self-reported cognitive problems in women receiving adjuvant therapy for breast cancer. Eur J Oncol Nursing. 2007;11:6–15. doi: 10.1016/j.ejon.2006.02.005.
    1. Hurria A, Somlo G, Ahles T. Renaming “chemobrain”. Cancer Invest. 2007;25(6):373–7. doi: 10.1080/07357900701506672.
    1. Falleti MG, Sanfilippo A, Maruff P, Weih L, Phillips KA. The nature and severity of cognitive impairment associated with adjuvant chemotherapy in women with breast cancer: a meta-analysis of the current literature. Brain Cogn. 2005;59:60–70. doi: 10.1016/j.bandc.2005.05.001.
    1. Matsuda T, Takayama T, Tashiro M, Nakamura Y, Ohashi Y, Shimozuma K. Mild cognitive impairment after adjuvant chemotherapy in breast cancer patients—evaluation of appropriate research design and methodology to measure symptoms. Breast Cancer. 2005;12:279–87. doi: 10.2325/jbcs.12.279.
    1. Bender CM, Paraska KK, Sereika SM, Ryan CM, Berga SL. Cognitive function and reproductive hormones in adjuvant therapy for breast cancer: a critical review. J Pain Symptom Manage. 2001;21:407–24. doi: 10.1016/S0885-3924(01)00268-8.
    1. Gross J. Chemotherapy is no longer ignored as illusion. The New York Times; 29 Apr 2007.
    1. Hoag H. The foggy world of chemobrain. The Toronto Star; 3 Nov 2007.
    1. Breast cancer: new software program helps breast cancer survivors and patients fight chemofog. Drug Week; 19 Oct 2007.
    1. Fitch MI, Armstrong J, Tsang S. Patients’ experiences with cognitive changes after chemotherapy. Can Oncol Nurs J. 2008;18(4):180–92.
    1. Downie FP, Mar Fan HG, Houédé-Tchen N, Yi Q, Tannock IF. Cognitive function, fatigue, and menopausal symptoms in breast cancer patients receiving adjuvant chemotherapy: evaluation with patient interview after formal assessment. Psychooncology. 2006;15(10):921–30. doi: 10.1002/pon.1035.
    1. Crabtree BF, Miller WL. Doing qualitative research. Sage: Newbury Park; 1992.
    1. University of Rochester Medical Center. 82% of cancer patients report ‘chemo brain’ during, after treatment. Press release, June 5, 2006. Available from .

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa